Aardvark Therapeutics (NASDAQ:AARD) Insider Nelson Sun Sells 62,000 Shares of Stock

Aardvark Therapeutics, Inc. (NASDAQ:AARD) insider Nelson Sun sold 62,000 shares of the stock in a transaction on Friday, September 11th. The shares were sold at an average price of $5.18, for a total value of $321,160.00. Following the completion of the transaction, the insider directly owned 35,475 shares of the company’s stock, valued at approximately $183,760.50. This represents a 63.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Nelson Sun also recently made the following trade(s):

• On Thursday, September 10th, Nelson Sun sold 14,754 shares of Aardvark Therapeutics stock. The shares were sold at an average price of $5.00, for a total value of $73,770.00.

Aardvark Therapeutics Trading Up 2.4%

NASDAQ:AARD opened at $5.13 on Friday. The company’s 50-day moving average price is $6.29 and its 200-day moving average price is $5.53. The company has a market cap of $112.26 million, a P/E ratio of -1.60 and a beta of 3.74. Aardvark Therapeutics, Inc. has a twelve month low of $3.35 and a twelve month high of $17.94.

Aardvark Therapeutics (NASDAQ:AARD) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.21. On average, analysts expect that Aardvark Therapeutics, Inc. will post -3.17 earnings per share for the current year.

Key Headlines Impacting Aardvark Therapeutics

Here are the key news stories impacting Aardvark Therapeutics this week:

• Positive Sentiment: No company-specific clinical, regulatory, or financial improvement was reported in the latest updates. The absence of new adverse operating news may limit additional selling pressure.
• Neutral Sentiment: Several law firms—including Hagens Berman, Rosen Law Firm, SBS Law, Pomerantz, Faruqi & Faruqi, and Bernstein Liebhard—are soliciting investors to seek lead-plaintiff status by October 13, 2026. These announcements largely repeat the same underlying lawsuit rather than representing separate cases. Hagens Berman investor notice
• Neutral Sentiment: A reported September short-interest update showed zero shares sold short, but the figures appear incomplete or unreliable because the reported change was listed as “NaN.” It therefore provides little useful insight into trading direction.
• Negative Sentiment: The securities class action covers investors who bought Aardvark shares in or traceable to the February 2025 IPO, or who purchased securities between February 13, 2025, and May 14, 2026. The litigation alleges violations of federal securities laws by the company and certain officers and directors. Pomerantz class-action announcement
• Negative Sentiment: One investor notice alleges that IPO materials described Aardvark’s ARD-101 drug candidate as 99% restricted to the gut and reported no serious adverse events, while allegedly omitting safety risks that later led to an FDA clinical hold. These remain allegations, but the claims create potential legal costs, uncertainty, and reputational damage. AARD shareholder alert

Wall Street Analysts Forecast Growth

AARD has been the subject of a number of analyst reports. Wall Street Zen upgraded Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Morgan Stanley reiterated an “underweight” rating and set a $3.00 price objective (down from $7.00) on shares of Aardvark Therapeutics in a research report on Friday, May 15th. Weiss Ratings upgraded Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 2nd. B. Riley Financial lowered their price objective on Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Finally, HC Wainwright restated a “neutral” rating and issued a $6.00 target price on shares of Aardvark Therapeutics in a report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Aardvark Therapeutics has an average rating of “Hold” and a consensus target price of $15.33.

Institutional Trading of Aardvark Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC boosted its stake in Aardvark Therapeutics by 5.9% during the third quarter. Citadel Advisors LLC now owns 1,359,883 shares of the company’s stock worth $18,073,000 after buying an additional 76,151 shares during the period. Laurion Capital Management LP raised its stake in shares of Aardvark Therapeutics by 6.1% in the 3rd quarter. Laurion Capital Management LP now owns 1,049,721 shares of the company’s stock valued at $13,951,000 after acquiring an additional 60,653 shares during the period. Vanguard Group Inc. raised its stake in shares of Aardvark Therapeutics by 20.6% in the 3rd quarter. Vanguard Group Inc. now owns 555,721 shares of the company’s stock valued at $7,386,000 after acquiring an additional 94,744 shares during the period. Millennium Management LLC lifted its holdings in shares of Aardvark Therapeutics by 51.2% in the 4th quarter. Millennium Management LLC now owns 483,340 shares of the company’s stock worth $6,344,000 after acquiring an additional 163,717 shares during the last quarter. Finally, SymBiosis Capital Partners LLC acquired a new position in shares of Aardvark Therapeutics in the 4th quarter worth approximately $6,255,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.